>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow BIRDHOUSE SALES SOAR FOR YOUTH

BIRDHOUSE SALES SOAR FOR YOUTH Print E-mail
September 23, 2008 11:00 pm
Jesse Orozco, left, and Curry Coastal Pilot ad rep Larry Bell show birdhouses made by the eighth-grader. (The Pilot/Marjorie Woodfin).
Jesse Orozco, left, and Curry Coastal Pilot ad rep Larry Bell show birdhouses made by the eighth-grader. (The Pilot/Marjorie Woodfin).

By Marjorie Woodfin

Pilot staff writer

One Brookings eighth grader is already thinking and planning for the future.

Jesse Orozco explained that his plans include a degree in marine biology from University of California at Santa Barbara because he wants to be a marine biologist.

Jesse isn't just thinking and dreaming; he's making strides toward financing his dream. He is building and selling birdhouses to save toward his college tuition, and he already has a great start.

Recently, as a business owner, Jesse came to the Curry Coastal Pilot to purchase an ad. When the ad rep told the editor about the young man, the story served as inspiration for a new business article.

Jesse was asked to bring samples of his work to the newspaper office for a photo to accompany the business story. When he brought two of his birdhouses in for the photo, he sold both of them on the spot and took orders for an additional 20.

Staff members who purchased or ordered the birdhouses said they were buying Christmas gifts and encouraged Jesse to take his birdhouses to the big Brookings Harbor Community Christmas Bazaar at the high school in November. He already planned to do that.

Jesse gave his grandfather credit for inspiring him and helping him get started with his project. He explained that his uncle, who is a roofer, had a lot of shakes removed from roofs he repaired and the shakes make great material for building the little houses. The weathered shakes and the moss trim make the romantic looking little houses very attractive, appealing, and hard to resist.

Those who don't want to wait for the Christmas bazaar to see the birdhouses can find Jesse's ad in the Pilot, or call his cell phone, (541) 661-8199.

 

Business News by Yahoo Finance

  • China shares lead Asia higher, dollar buoyed
    Asian stocks shrugged off a drop in Wall Street and hovered near three-year highs on Monday, with China taking the lead after data showed a robust jump in profits earned by industrial firms in the world's second-largest economy. The two-day Federal Reserve policy review ending on Wednesday was also in focus but expectations were for Chair Janet Yellen to deliver the usual dovish message.
  • JP Morgan questioned on private bank impropriety: WSJ
    As a result of the questioning regarding potential conflicts of interest, the New York-based bank has sharpened its disclosures to clients, the newspaper said, citing sources. The Office of the Comptroller of the Currency, one of JP Morgan's regulators, has been in discussions with the bank regarding the potential conflicts of interest in recent months, according to the report. "Being transparent is part of our normal course of business and it's what drives our client communications," Darin Oduyoye, a spokesman for JP Morgan's asset-management unit, told Reuters on Sunday. If brokers push clients to buy the in-house brand of financial product, rather than provide impartial financial advice, the bank could stand to benefit at the expense of the client.
  • Pfizer's need for deal looms larger with earnings report
    Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck & Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials of promising products - including breast cancer drug palbociclib and vaccines against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares.     "Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations," he said.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use